RHOA and Burkitt lymphoma: Another study also showed inactivating mutations in components of the GPCR signaling pathway (i.e. GNA13 and RHOA) genes, suggesting that this pathway may be a target of therapy for GNA13 or RHOA-mutated BL cases (O’Hayre et al., 2016).